Anthem Biosciences Limited has given an undertaking before the Delhi High Court saying that it will not launch any product using anti-cancer drug Alectinib [Chugai Seiyaku Kabushiki Kaisha & Anr v. Anthem Biosciences Limited].
Justice Tejas Karia issued notice to the Bangalore-based company on an application filed by Japanese drug manufacturing company Chugai Pharmaceutical in its patent infringement suit against Anthem.
The Court recorded an undertaking that till the next date of hearing, Anthem Biosciences will not launch any product that infringes Chugai Pharmaceutical's patents .
"Learned Counsel for the Defendant, on instructions, submits that till the next date of hearing, the Defendant shall not launch any product dealing with Alectinib or its salt or solvates or intermediate(s) that infringes the Plaintiffs’ patent granted vide Indian Patent No. IN 294424," the Court recorded in the order.
The next date of hearing is October 9.
In its patent infringement suit, Chugai Pharmaceutical has sought information from Anthem Biosciences to determine the process employed to manufacture its biosimilar product using the anti-cancer drug.
By way of an interim injunction application, Chugai is also seeking directions to restrain Anthem Biosciences from using Alectinib or its salts, solvents or intermediates.
Advocates Pravin Anand, Shrawan Chopra, Achyut Tiwari and Krisha Baweja appeared for Chugai Seiyaku Kabushiki Kaisha.
Advocates Amrita Majumdar and Samik Mukherjee appeared for Anthem Biosciences.
[Read order]